# An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

> **NCT05123365** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 27 (estimated)

## Conditions studied

- Myeloproliferative Neoplasm
- MPN
- Essential Thrombocythemia
- Polycythemia Vera
- Myelofibrosis

## Interventions

- **DRUG:** N-Acetylcysteine

## Key facts

- **NCT ID:** NCT05123365
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-03
- **Primary completion:** 2026-11-15
- **Final completion:** 2026-11-15
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123365, "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05123365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*